Swissmedic began rolling review of Moderna’s mRNA vaccine against COVID-19
On Nov. 13, 2020, Moderna announced that Swissmedic had started a rolling review of mRNA-1273, the Company’s vaccine…
CALAVI did not meet the primary endpoint in patients hospitalised with respiratory symptoms of COVID-19
On Nov. 12, 2020, AstraZeneca announced that the CALAVI Phase II trials for Calquence (acalabrutinib) in patients hospitalised…
Sorrento announced IND filing for COVI-DROPS against SARS-CoV-2
On Nov. 11, 2020, Sorrento Therapeutics announced that it was filing an investigational new drug application (IND) for…
DSMB analysis recommended continuance of P3 COVID-19 ARDS trial
On Nov. 11, 2020, Mesoblast announced that the randomized controlled Phase 3 trial of remestemcel-L in patients with…
Mateon and Windlas Biotech announced agreement to commercialize ARTIVEDA against COVID-19
On Nov. 11, 2020, Mateon Therapeutics announced an agreement with Windlas Biotech of India to commercialize ARTIVeda. ARTIVeda…
Medigen Vaccines and BlueWillow Biologics partnered to Develop intranasal vaccine for SARS-COV-2
On Nov. 19, 2020, Medigen Vaccine Biologics and BlueWillow Biologics announced a partnership to develop S-2P-NE-01, a nasal…
Biotechnology | HIV | Life Science News | NIH | Therapeutics
Long-acting injectable drug prevented HIV in cisgender women
On Nov. 9, 2020, the NIH reported that a pre-exposure prophylaxis (PrEP) regimen containing an investigational long-acting form…
Hydroxychloroquine does not benefit adults hospitalized with COVID-19
On Nov. 9, 2020, a National Institutes of Health (NIH) clinical trial evaluating the safety and effectiveness of…
Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19
On Nov. 9, 2020, a study published in JAMA reported the effect of hydroxychloroquine on clinical status at…
Ultragenyx announced plans to build large-scale gene therapy manufacturing facility for rare diseases
On Nov. 9, 2020, Ultragenyx announced that it planned to build a new large-scale gene therapy manufacturing facility…
Pfizer and BioNTech announced vaccine candidate against COVID-19 achieved success in interim analysis from phase 3 study
On Nov. 9, 2020, Pfizer and BioNTech announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 had demonstrated evidence…
Humanigen announced CRADA agreement with U.S. government to develop lenzilumab for COVID-19
On Nov. 6, 2020, Humanigen announced that it had entered into a Cooperative Research and Development Agreement (CRADA)…
Thermo Fisher Scientific and Innoforce established biologics and steriles drug manufacturing facility in China
On Nov. 6, 2020, Thermo Fisher Scientific and Innoforce announced a joint venture agreement to establish a new…
Mateon’s C001- A Global phase 2 study for OT-101 against COVID-19 received cleareence for patient enrollment
On Nov. 4, 2020, Mateon Therapeutics announced the receipt of approval from Instituto Nacional de Salud (INS), the…
Biotechnology | Diagnostics | Disease | Life Science News | Oncology | Therapeutics | Women's Health
McGill University Professor William Foulkes awarded 2020 Wilder-Penfield Prize for research in the genetics of breast and ovarian cancer
On Nov. 4, 2020, McGill University Professor William Foulkes awarded 2020 Wilder-Penfield Prize for research in the genetics…
City of Hope opened clinical trial for cancer patients with COVID-19
On Nov. 3, 2020, City of Hope announced that it is investigating an innovative treatment for cancer patients…
Biotechnology | COVID-19 | Life Science News | Medicine | NIH | Therapeutics | Vaccine
Medigen Vaccines and NIHE partnered to develop COVID-19 vaccine in Vietnam
On Nov. 3, 2020, Medigen Vaccine Biologics (MVC) and the National Institute of Hygiene and Epidemiology (NIHE), a…
Humanigen executed licensing agreement for Lenzilumab in COVID-19 for South Korea and the Philippines
On Nov. 3, 2020, Humanigen announced the execution of its first licensing transaction in the Asia-Pacific Region with…
COVID-19 pandemic sparked 3D printing engineering innovation
On Nov. 2, 2020, Pacific Northwest National Laboratory (PNNL) announced that in the Spring of 2020, as news…
Patriot Express Travel at BWI, SEATAC required on-site, rapid COVID-19 testing
On Nov. 1, 2020, the U.S. Department of Defense announced the start of rapid, on-site COVID-19 testing for…
Brilacidin exhibited potent in vitro antiviral activity against SARS-CoV-2
On Nov. 1, 2020, scientists announced that increasing evidence shows that both natural and synthetic antimicrobial peptides (AMPs),…
Lilly announced agreement with US government to supply 300,000 vials of investigational neutralizing antibody bamlanivimab to fight COVID-19
On Oct. 28, 2020, Eli Lilly announced an initial agreement with the U.S. government to supply 300,000 vials…
Aspirin use best for those with high coronary calcium, low risk of bleeding
On Oct. 28, 2020, University of Texas (UT) Southwestern scientists reported that an X-ray test commonly used to…
Seagen announced closing of $1.0 billion stock sale to Merck
On Oct. 28, 2020, Seagen announced the closing of a $1.0 billion equity investment by Merck in 5.0…
Biotechnology | Diagnostics | Disease | Genomics | Life Science News | NIH | Therapeutics
Scientists used clues in the human genome to discover new inflammatory syndrome
On Oct. 27, 2020, researchers from the National Institutes of Health (NIH) announced they had discovered a new…
ViralClear halted its phase 2 hospitalized COVID-19 trial
On Oct. 26, 2020, BioSig Technologies and its majority owned subsidiary, ViralClear Pharmaceuticals, announced the halting of its…
Amyris and the Infectious Disease Research Institute entered into exclusive license for novel RNA vaccine platform
On Oct. 22, 2020, Amyris and the Infectious Disease Research Institute (IDRI) announced the signing of a Collaboration…
FDA approved Gilead’s antiviral Veklury (remdesivir) for treatment of COVID-19
On Oct. 22, 2020, Gilead Sciences announced that the FDA had approved the antiviral drug Veklury (remdesivir) for…
ViiV Healthcare analysis showed no antiretroviral therapy interruptions due to COVID-19
On Oct. 21, 2020, ViiV Healthcare, majority owned by GSK, with Pfizer and Shionogi Limited as shareholders, announced…
Agriculture | Artificial Intelligence | Biotechnology | CMO | CRO | Life Science News | Non-Profit Research | Pharmaceutical | Therapeutics | U.S. Congress | Vaccine
U.S. Department of Defense approved $87 million for newest bioindustrial manufacturing innovation institute
On Oct. 20, 2020, the U.S. Department of Defense announced an $87 million, seven-year award to the BioIndustrial…